FirstWord

FirstWord is a major healthcare intelligence provider worldwide. The customers are offered upscale reports on various sectors of pharmaceutical industry. Research is carried out by best specialists in pharma market who ensure the clients with unique data, deep insight into the issue, latest events and new technologies.

The experts have access to reliable and abounding data resources to perform qualitative and extensive pharma reports. The area under study involves: biosimilars, medications, orphan drugs, patient-centric disease treatment and healthcare technologies.

In the reports customers will find basic market information on the products and the following takeaways:
  • Leading and emerging trends;
  • Medical enterprises;
  • Critical analysis for best strategies;
  • Multichannel marketing modelling to guide the customers to the right channels and content;
  • Key success factors and opportunities for pharma industry;
  • Pharma sales analysis; etc.
FirstWord helps you stay competitive, get 5 year forecast and improve productive efficiency. To acquire measurable and sufficient outcome it is vital to use FirstWord consulting service.

Research Reports By FirstWord

Found 642 publications
The Future of Market Access in Europe US$ 2,245.00 Oct, 2017
NPS+ (US) [Myeloma] US$ 2,575.00 Oct, 2017
Alzheimer's Disease [2017] US$ 8,145.00 Oct, 2017
NPS+ (EU5) [Myeloma] US$ 2,575.00 Oct, 2017
Prostate Cancer [2017] US$ 8,145.00 Oct, 2017
The Future of Market Access in US US$ 2,245.00 Oct, 2017
Medical Affairs Reputations (US) [RA] US$ 6,175.00 Oct, 2017
RCC [2017]: Bulletin #1 US$ 1,045.00 Sep, 2017
NPS+ (EU5) [CLL] US$ 2,575.00 Sep, 2017
Ulcerative Colitis [2017] US$ 8,145.00 Sep, 2017
Market Access Impact (EU5) [Myeloma] US$ 5,145.00 Sep, 2017
Market Access Impact (US) [Myeloma] US$ 5,145.00 Sep, 2017
Type 2 Diabetes Mellitus [2017] US$ 8,145.00 Sep, 2017
Colorectal Cancer [2017] US$ 8,145.00 Sep, 2017
Atopic Dermatitis [2017] US$ 8,145.00 Sep, 2017
Multiple Myeloma [2017]: Bulletin #1 US$ 1,045.00 Sep, 2017
NPS+ (US) [CLL] US$ 2,575.00 Sep, 2017
NPS+ (EU5) [RA] US$ 2,575.00 Aug, 2017
Breast Cancer [2017]: Bulletin #1 US$ 1,045.00 Aug, 2017
AML [2017]: Bulletin #2 US$ 1,045.00 Aug, 2017
Melanoma [2016]: Bulletin #3 US$ 1,045.00 Aug, 2017
Market Access Impact (EU5) [NSCLC] US$ 5,145.00 Aug, 2017
Market Access Impact (US) [NSCLC] US$ 5,145.00 Aug, 2017
1 2 3 4 5 ... 13
Skip to top

Analytics, News & Press-Releases by FirstWord